SciSparc says Clearmind files three new international patent applications

SciSparc Ltd. (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), Clearmind filed three patent applications under the international Patent Cooperation Treaty. The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine, ibogaine, and ketamine, each combined with palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office. As part of this collaboration, eight other applications have been filed by Clearmind with the USPTO for various combinations, three of which are for the combination of PEA with Clearmind’s 5-methoxy-2-aminoindane compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders. In addition, seven applications were filed under the PCT.